331 related articles for article (PubMed ID: 17325590)
21. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
22. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
[TBL] [Abstract][Full Text] [Related]
23. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
24. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies.
Jeong HS; Chung MK; Son YI; Choi JY; Kim HJ; Ko YH; Baek CH
J Nucl Med; 2007 Aug; 48(8):1237-44. PubMed ID: 17631549
[TBL] [Abstract][Full Text] [Related]
25. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
26. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma.
Freudenberg LS; Schueler AO; Beyer T; Antoch G; Kühl H; Bornfeld N; Bockisch A; Egelhof T
Surv Ophthalmol; 2004; 49(5):537-40. PubMed ID: 15325198
[TBL] [Abstract][Full Text] [Related]
27. FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma.
Ryan ER; Hill AD; Skehan SJ
Clin Nucl Med; 2006 Nov; 31(11):707-8. PubMed ID: 17053391
[TBL] [Abstract][Full Text] [Related]
28. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
29. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
30. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
32. Association of positive dual-modality positron emission tomography/computed tomography imaging of primary choroidal melanoma with chromosome 3 loss and tumor size.
McCannel TA; Reddy S; Burgess BL; Auerbach M
Retina; 2010 Jan; 30(1):146-51. PubMed ID: 20010323
[TBL] [Abstract][Full Text] [Related]
33. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study.
Nguyen NC; Tran I; Hueser CN; Oliver D; Farghaly HR; Osman MM
Clin Nucl Med; 2009 Dec; 34(12):886-90. PubMed ID: 20139823
[TBL] [Abstract][Full Text] [Related]
34. Characterization of T-cell lymphomas by FDG PET/CT.
Feeney J; Horwitz S; Gönen M; Schöder H
AJR Am J Roentgenol; 2010 Aug; 195(2):333-40. PubMed ID: 20651187
[TBL] [Abstract][Full Text] [Related]
35. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
36. Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography.
Francken AB; Hong AM; Fulham MJ; Millward MJ; McCarthy WH; Thompson JF
Eur J Surg Oncol; 2005 Mar; 31(2):197-204. PubMed ID: 15698738
[TBL] [Abstract][Full Text] [Related]
37. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies.
Kamel EM; Jichlinski P; Prior JO; Meuwly JY; Delaloye JF; Vaucher L; Malterre J; Castaldo S; Leisinger HJ; Delaloye AB
J Nucl Med; 2006 Nov; 47(11):1803-7. PubMed ID: 17079813
[TBL] [Abstract][Full Text] [Related]
38. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
39. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
Niebling MG; Bastiaannet E; Hoekstra OS; Bonenkamp JJ; Koelemij R; Hoekstra HJ
Ann Surg Oncol; 2013 Sep; 20(9):3098-105. PubMed ID: 23612885
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
